Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Colorcon
Healthtrust
Farmers Insurance
QuintilesIMS
Argus Health
Moodys
Daiichi Sankyo
Dow
Fuji

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,604,213

« Back to Dashboard

Which drugs does patent 5,604,213 protect, and when does it expire?

Patent 5,604,213 protects ZYTIGA and is included in one NDA.

This patent has forty patent family members in nineteen countries.
Summary for Patent: 5,604,213
Title: 17-substituted steroids useful in cancer treatment
Abstract:Compounds of the general formula (1) ##STR1## wherein X represents the residue of the A, B and C rings of a steroid, R represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R.sup.14 represents a hydrogen atom and R.sup.15 represents a hydrogen atom or an alkyl or alkoxy group of 1-4 carbon atoms, or a hydroxy or alkylcarbonyloxy group of 2 to 5 carbon atoms or R.sup.14 and R.sup.15 together represent a double bond, and R.sup.16 represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, in the form of the free bases or phannaceutically acceptable acid addition salts, are useful for treatment of androgen-dependent disorders, especially prostatic cancer, and also oestrogen-dependent disorders such as breast cancer.
Inventor(s): Barrie; Susan E. (Kent, GB3), Jarman; Michael (London, GB3), Potter; Gerard A. (Cheshire, GB3), Hardcastle; Ian R. (Sutton, GB3)
Assignee: British Technology Group Limited (London, GB2)
Application Number:08/315,882
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 5,604,213

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Biotech ZYTIGA abiraterone acetate TABLET;ORAL 202379-001 Apr 28, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ➤ Subscribe
Janssen Biotech ZYTIGA abiraterone acetate TABLET;ORAL 202379-001 Apr 28, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,604,213

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9207057Mar 31, 1992
United Kingdom9224880Nov 27, 1992
United Kingdom9320132Sep 30, 1993
United Kingdom9414192Jul 14, 1994

Non-Orange Book US Patents Family Members for Patent 5,604,213

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,618,807 Method for preparing 17-substituted steroids useful in cancer treatment ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,604,213

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 7661894 ➤ Subscribe
Canada 2132449 ➤ Subscribe
Canada 2170286 ➤ Subscribe
Czech Republic 9402337 ➤ Subscribe
Czech Republic 287434 ➤ Subscribe
Germany 69327096 ➤ Subscribe
Germany 69416419 ➤ Subscribe
Germany 122012000012 ➤ Subscribe
Denmark 0633893 ➤ Subscribe
Denmark 0721461 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
McKinsey
Boehringer Ingelheim
Novartis
Cerilliant
Moodys
Chinese Patent Office
Teva
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot